Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...

Which of the statements about the diagnosis and management of difficult-to-treat rheumatoid arthritis are correct?

The first time Dr. Fajgenbaum repurposed a drug, it was in an attempt to save his own life. At 25, while in medical school, ...